Page results
-
Media statement UCLH chief executive David Probert said: “Many congratulations to Carrie and Boris Johnson on the birth of their baby daughter Romy Iris Charlotte Johnson. We wish…
-
UCLH doctor 1 of 10 international members elected to National Academy of Medicine
-
We are asking patients to follow some protocols before they come to UCLH and would appreciate it if you could reiterate this with your patients when you refer them.
-
Whilst the UCLH paediatric emergency department remains on divert, access for GPs to paediatrics remains available as usual.
-
The court has granted permission to appeal a High Court ruling relating to puberty-blocking treatment in cases of gender dysphoria.
-
Improvements to patient care underpinned the UCLH presentations at the weekend’s European Association of Urology conference in Paris
-
Two UCLH nurses who have dedicated their entire career to the NHS were invited to attend a VE Day celebration concert last Thursday.
-
The spring/summer edition of Charity Matters is out now.
-
UCLH’s trial of the world’s first ‘gene silencing’ drug for Alzheimer’s disease has progressed into a larger and later stage trial, after promising early results.
-
An international clinical trial testing a novel cancer immunotherapy which may prevent skin cancer from recurring has recruited its first patients at UCLH.
File results
-
FOI/2024/0582 - SACT (systemic anti-cancer therapy) treatments for endometrial cancer
-
FOI/2024/0583 - National inpatient survey improvements/ night-time noise levels/ ward lighting/ mealtime support
-
FOI/2024/0584 - Immunology Hidradenitis Suppurativa (HS) treatments
-
FOI/2024/0586 - Subject Access Requests (SAR) and Freedom of Information (FOI) requests for 2023/24
-
FOI/2024/0587 - Colorectal cancer treatments
-
FOI/2024/0589 - SACT Cancer report/ Drug Patient Level Contract Monitoring (DrPLCM) report
-
FOI/2024/0594 - Implementation of Federated Data Platform (FDP) and procurement of data platforms
-
FOI/2024/0595 - Capital estate activity for 2020-2024
-
FOI/2024/0597 - Urothelial cancer treatments
-
FOI/2024/0605 - Finance software system/ installation and expiry of software